Index. Springer Nature Singapore Pte Ltd K. Lahiri (ed.), A Treatise on Topical Corticosteroids in Dermatology, DOI /
|
|
- Percival Short
- 5 years ago
- Views:
Transcription
1 A Abuse, topical steroids Africa perspective adverse effects, 230 allergic dermatitis, 233, 234 bleaching creams, 229, 230 complications, 230 Cushing syndrome, 234, 235 dyschromia, 233, 234 gluteal granuloma infantum, 234 hypertrichosis, 234 pustulosis psoriasis and the dermocorticoids, skin atrophy, 233, 234 skin infections, striae distensae, Australian perspective atopic dermatitis, 238 attitudes and behaviour, eczema, 238 guidelines, 238 overuse, research, 238 use, in Bangladesh bleaching effects, 201 cosmetics, 201 creams, 201 effect and potency, 198 grades, 198 improper and wrong use, 201 misuse, 200 side effects/adverse effects, use for, 197, 198 clinical manifestations, 133 cosmetic cream epidemiology, response, education, 304 epidemiology of, fairness craze, dermatologists, 304 governmental agencies, 305 industry, 305 non-dermatologists, 304 paramedical staff, patients and public, hidden danger, 132 imbricated tinea, 324 Indian perspective, 180 awareness campaign, effects, 183 face, side effects, 182 historical aspects, 180 indications, misuse, 181 less-known cutaneous side effects, 183 magnitude, measurement, 186 misuse, reasons, 180 ocular complications, 183 over the counter drugs, 180 population, 181 sales, 181 side effects, 182 stages, misuse, studies on, 185 systemic side effects, 183 task force, treatment, 186 types, 181 Japanese perspective advocacy, 226 atopic dermatitis, Japanese Dermatological Association Guidelines, 226 doctors prescription, 224 Internet use, 227 lawsuit, 225 media and topical steroid use, 225 medical malpractice claims, NHI system and drug price margins influence, overservicing, 224 over the counter drugs, 223, 226 precautions, over the counter topical steroids, lupus vulgaris, 322 Majocchi s granuloma, 321, 324 malassezia folliculitis, 321 Springer Nature Singapore Pte Ltd K. Lahiri (ed.), A Treatise on Topical Corticosteroids in Dermatology, DOI /
2 326 Abuse, topical steroids(cont.) menacing proportions, 301 in Middle East, 206 adult population, education, 207 pediatric population, 206 pigmentary disorders, 207 prescription, 207 in Nepal, disease distribution, 194 facial dermatosi, 194, 195 over the counter drugs, 191 patient perspective, 191 significant amount, 195 steroid-induced dermatosis, steroids, 194 tinea incognito, procedural techniques acne and acneiform eruptions, telangiectasia and steroid-induced rosacea, 280 psoriasis Koebnerizing, 322 regulatory aspects Africa, jungle of law, 288 blanket ban, 287 COOT cocktail, 286 drug control authorities, 284 European Union legislation, 288 fairness, misuse of steroid creams, 287 fixed drug combinations, 284 imitators, Indian drug regulation scene, irrational steroid, plethora of, menace, 288 point of sale, 288 price control angle, 287 schedule H tragedy and legislation, 285 response, side effects and management, 278 Southeast Asia, 210 acneiform eruptions, 213, adverse reactions, 221 axillary regions, 212 Cushing s syndrome, 221 factors, fungal infections, furunculosis and folliculitis, 217, 219, 220 guidelines, 221 inner arms, striae, 212 perilesional hypopigmentation, 217, 220 perioral dermatitis, 213, 217 potency, 221 psoriasis teenage, 211 psoriatic Indonesian patient, 212 psoriatic Singaporean patient, 211 skin atrophy, 212, 215 telangiectasia, 212, 214 tinea faciei, 322, 323 topical steroid-induced striae, 323 TSDF, 302 Index ulceration, 322, 324 widespread tinea, 323 Acne, 231, 233, Acneiform eruption abuse Africa, 231, 232 Nepal, 193 Southeast Asia, 213, adverse effects, 113 management, procedural techniques, topical side effects, 255 TSDF, 141 Addiction, 123, 133, 148, 262, 284. See also Topical corticosteroid addiction (TCA) Addison s disease, 4 ADR. See Adverse drug reaction (ADR) Adrenocortical insufficiency, 312 Adverse drug reaction (ADR), 19 20, 292 Africa, topical steroid abuse adverse effects, 230 allergic dermatitis, 233, 234 bleaching creams, 229, 230 complications, 230 Cushing syndrome, 234, 235 dyschromia, 233, 234 gluteal granuloma infantum, 234 hypertrichosis, 234 pustulosis psoriasis and the dermocorticoids, skin atrophy, 233, 234 skin infections, striae distensae, AIBDs. See Autoimmune blistering diseases (AIBDs) Allergic contact dermatitis, 145, 233, 234 Alopecia areata, 65, 103 intralesional steroids, topical corticosteroids, 104 Alopecia areata (AA), Androgenetic alopecia, 105 Anogenital pruritus, 65 Antifungal shampoos, Arciform lesions, Atopic dermatitis (AD) dermatological indications and usage, eczematous lesion of, 111 Japanese Dermatological Association Guidelines, 226 phobia, 268 rational use, 120 research, 238 RSS, 170 Atrophogenecity, 166 Atrophy alopecia areata, intralesional steroids, 103 genital dermatosis, 165 side effects, dermal atrophy, 254 epidermal atrophy, 254 purpura and easy bruisability, 254 stellate pseudoscars,
3 striae, 254 telangiectasia, 254 TSDF, 146 Australia, TCS use and overuse atopic dermatitis, 238 attitudes and behaviour, eczema, 238 guidelines, 238 overuse, research, 238 use, Autoimmune blistering diseases (AIBDs), 92 adrenal suppression, 97 bullous pemphigoid, 93 evidence, guidelines, international management, 95 EBA, 97 linear IgA disease, 97 MMP, 96 pemphigoid gestationis, pharmacology chemical structure, 92 mechanism of action, PV and PF, side effects, Autoimmune dermatoses, 83 Awareness, B Bacterial infections, 217, 231, 232, Balanitis xerotica obliterans, Balanoposthitis, Bangladesh, topical corticosteroid abuse bleaching effects, 201 cosmetics, 201 creams, 201 effect and potency, 198 grades, 198 improper and wrong use, 201 misuse, 200 side effects/adverse effects, use for, 197, 198 Betamethasone, 6, 13 Betnovate C, 287 Black Triangle Drugs, 293 Blistering diseases adrenal suppression, 97 bullous pemphigoid, 93 evidence, guidelines, international management, 95 EBA, 97 linear IgA disease, 97 MMP, 96 pemphigoid gestationis, pharmacology chemical structure, 92 mechanism of action, PV and PF, side effects, Blistering disorders, Blue card, 239 Breastfeeding, 26 27, 88, 89 Bullous pemphigoid (BP), 93 evidence, experimental model, 92 guidelines, international management, 95 randomized controlled trials, 63 Burns, C Calcineurin inhibitors, 166 Candida albicans, 257 Candidial balanoposthitis, Cayenne pepper spots, 162 Central centrifugal cicatricial alopecia (CCCA), 106 Chemical peel, 279, 281 Children, pediatric age group, adverse effects, measurement, 115 misuse of, use of, Cicatricial alopecias, Circumcision, 166 CLE. See Cutaneous lupus erythematosus (CLE) Clobetasol-ofloxacin-ornidazole and terbinafine (COOT) cocktail, 286 Clobetasol propionate (CP), 82, 92, 93, 106 Clocortolone pivalate, 6 Committee on the Safety of Medicines (CSM), 293 Compound F. See Hydrocortisone Contact dermatitis (CD), 30 Contact hypersensitivity, Contact sensitization, COOT cocktail. See Clobetasol-ofloxacin-ornidazole and terbinafine (COOT) cocktail Corporis, 153 Corticosteroid-binding globulin (CBG), 82 Cortisol, 13, 26, 27, 83, 172, 176, 252, 271 Cortisone, 3, 4, 172 Cosmetics abuse epidemiology, response, popularity, TCS, Council for International Organizations of Medical Sciences (CIOMS), 294 Counselling, 115 Cream, 18 19, 102, 119 Crusted scabies, 232 Cushing s syndrome, 221, 234, 235, 244, 312 Cutaneous lupus erythematosus (CLE), 33, 65 Cutaneous sarcoidosis, 36, 63 Cutaneous T-cell lymphoma (CTCL), 62
4 328 D Delayed wound healing, 258 Demodex folliculorum, 256 Dermal atrophy, 182, 254 Dermatoses, 4, 6, 88, 89, 113, 118, 160, 256 Dermocorticoids, Discoid lupus, 106 Double-edged tinea, 154 Drug price margin, Drugs and Cosmetics Act, 285 Drugs and Magic Remedies (Objectionable Advertisement) Act, 302 Drug withdrawal syndrome, Dumbbell-shaped large annular lesions, Dyschromia, 233, 234 E Eczema, 238 randomized controlled trials, systematic review, 43 EPDS. See Erosive pustular dermatosis of the scalp (EPDS) Epidermal atrophy, 254 Epidermolysis bullosa acquisita (EBA), 97 Erosive pustular dermatosis of the scalp (EPDS), 106 Erysipelas, 233 Erythema, 18, 113, 139, 199 Ethics issues beneficence vs. autonomy, non-malfeasance, 75 patient autonomy, 75 truth telling, 75 use of amount, frequency, and duration, 77 corticosteroid allergy, being aware of, 77 diagnosis, 76 effective communication, exit strategy, 77 molecule and delivery system, 76 patient, prevention and modifiable factors, focusing, 77 European Medicines Agency (EMA), 293 Europe, pharmacovigilance, 293 Evidence based approach bullous pemphigoid, 63 cutaneous sarcoidosis, 63 eczema, hand eczema, infantile hemangiomas, 64 lichen planus, miscellaneous conditions, 65 mycosis fungoides, pregnancy and lactation, 65 psoriasis, vitiligo, F Fetal growth restriction, 84 Fingertip unit (FTU) method, 77, 111, 120, 224 Fluocinolone acetonide, 5, Fluorinated agents, 4 5 9α-Fluorohydrocortisone acetate, 4 Folliculitis, 104, 217, 219, 220 Frontal fibrosing alopecia (FFA), 106 FTU method. See Fingertip unit (FTU) method Fungal infections, Furunculosis, 217, 219, 220 G Gels, 19, 102, 119 Genital dermatosis atrophy, 165 calcineurin inhibitors, 166 circumcision, 166 contact hypersensitivity, genitocrural region, microenvironment balanitis xerotica obliterans, balanoposthitis, females, genital pruritus, 164 LSA, 162 male, 160 plasma cell balanitis/zoon s balanitis, 162 plasma cell vulvitis, 163 pseudoepitheliomatous micaceous and keratotic balanitis, 163 vulvar lichen sclerosus atrophicus, side effects, Genital pruritus, 164 Genitocrural region, microenvironment balanitis xerotica obliterans, balanoposthitis, females, genital pruritus, 164 LSA, 162 male, 160 plasma cell balanitis/zoon s balanitis, 162 plasma cell vulvitis, 163 pseudoepitheliomatous micaceous and keratotic balanitis, 163 vulvar lichen sclerosus atrophicus, Gluteal granuloma infantum, 234 Granulomatous diseases, 36 Great Depression, 2, 3 H Haemangiomas, 34 Hair and scalp disorders alopecia areata, 103 intralesional steroids, topical corticosteroids in, 104 androgenetic alopecia, 105 categories, 102 cicatricial alopecias, EPDS, 106 formulations, polyamide, 106 polymeric nanocarriers, 106 scalp psoriasis, seborrhoeic dermatitis, 104 Index
5 Hand eczema, 30, Herpetic balanitis, Hirsutism, 141, 142, HPA axis. See Hypothalamic pituitary-adrenal (HPA) axis Human vasoconstriction assay, 7, 14 Hydrocolloid dressing, 31 Hydrocortisone, 3 5, 25, 30, 35, 87, 92, 130, 138, 163, 239, 252, 262, 284, β-Hydroxysteroid dehydrogenase (11βHSD), 26, 82, 83, 172, 176 Hyperglycemia, 246 Hyperlipidemia, 246 Hyperpigmentation, 75, 132, 144, 193, 233 Hypertension, 246 Hypertrichosis, 234, 255, Hypertrophic scars, 35 Hypopigmentation, 103, 144, 157, 182 Hypothalamic pituitary adrenal (HPA) axis, 244, 245 I Iatrogenic Cushing s syndrome, 244, 245 ICH. See International Council for Harmonisation (ICH) Idiopathic urticaria, chronic, 35 ILS. See Intralesional steroid (ILS) Imbricated tinea, 324 India regulatory aspects blanket ban, 287 COOT cocktail, 286 drug control authorities, 284 European Union legislation, 288 fairness, misuse of steroid creams, 287 fixed drug combinations, 284 imitators, Indian drug regulation scene, irrational steroid, plethora of, menace, 288 point of sale, 288 price control angle, 287 schedule H tragedy and legislation, 285 topical steroid abuse, 180 awareness campaign, effects, 183 face, side effects, 182 historical aspects, 180 indications, misuse, 181 less-known cutaneous side effects, 183 magnitude, measurement, 186 misuse, reasons, 180 ocular complications, 183 population, 181 sales, 181 side effects, 182 stages, misuse, studies on, 185 systemic side effects, 183 task force, treatment, 186 types, 181 Infantile hemangiomas, 64 Infestations, 257 Inflammatory dermatoses, 83 Intense pulsed light (IPL), 280 International Council for Harmonisation (ICH), 294 International Topical Steroid Addiction Network (ITSAN), associations, fixed drug combinations, 310 mission, 313 newsletter, RSS, 313 Intertrigo, 34 Intralesional steroid (ILS), 28, 35 ITSAN. See International Topical Steroid Addiction Network (ITSAN) J Japan pharmacovigilance, 293 topical steroid abuse advocacy, 226 atopic dermatitis, Japanese Dermatological Association Guidelines, 226 doctors prescription, 224 Internet use, 227 lawsuit, 225 media and topical steroid use, 225 medical malpractice claims, NHI system and drug price margins influence, overservicing, 224 over the counter drugs, 223, 226 precautions, over the counter topical steroids, K Keloid, 35 Keratinocyte, 18, 105, 172, 254 Keratotic balanitis, 163 Ketoconazole, 104 Kligman formula, 132, 148, 181, 185 L Labial adhesion, Lactation pros and cons of bioavailability, 88 hydrocortisone, 87 preparation, potency ranking, 88 safety of, randomized controlled trials, 65 Langerhans cells, 16 Laser therapy, 281 Leucotrichia, 112 Lichen planus (LP), 32 hypertrophicus, 112 randomized controlled trials, well-defined violaceous plaque of, 112 Lichen sclerosus, 35,
6 330 Lichen sclerosus et atrophicus (LSA), 162 Lichen simplex chronicus (LSC), 30 Linear IgA disease, 97 Lotion, 19, 102, 119 LSA. See Lichen sclerosus et atrophicus (LSA) Lupus vulgaris, 322 Lymphocytic microfolliculitis, 105 M Majocchi s granuloma, 257, 321, 324 Malassezia folliculitis, 321 Male genital dermatophytosis, Marker degradation, 3 Medicines and Healthcare Products Regulatory Agency (MHRA), 293 MedWatch, 293 Melasma, 35, 65 Metabolic disorders, 246 Microenvironment, genitocrural region balanitis xerotica obliterans, balanoposthitis, females, genital pruritus, 164 LSA, 162 male, 160 plasma cell balanitis/zoon s balanitis, 162 plasma cell vulvitis, 163 pseudoepitheliomatous micaceous and keratotic balanitis, 163 vulvar lichen sclerosus atrophicus, Middle East, topical corticosteroid use, 206 adult population, education, 207 pediatric population, 206 pigmentary disorders, 207 prescription, 207 Minoxidil, 105 MMP-9, 92 Mometasone furoate, 64, 106 Mucocele, 36 Mucous membrane pemphigoid (MMP), 96 Multiple small annular lesions, Mycoses, Mycosis fungoides, N National Health Insurance (NHI) system, Nepal, topical steroid abuse, disease distribution, 194 facial dermatosis, 194, 195 over the counter drugs, 191 patient perspective, 191 significant amount, 195 steroid, 194 steroid-induced dermatosis, tinea incognito, Neutrophils, 92 NHI system. See National Health Insurance (NHI) system Nitric oxide (NO), 264 Nitric oxide synthetase, 17 Nitro-glucocorticoids, 20 Nodulocystic acne, 36 O Occlusive dressing therapy, 28 Ocular adverse effects, 246 Ointments, 19, 102, 119 Orofacial cleft, 84 Index P Panderm Plus cream, 181 Papules, 139 Parasites, 231 Pemphigoid gestationis (PG), Pemphigus foliaceus (PF), Pemphigus vulgaris (PV), Perianal inflammation, 34 Perilesional hypopigmentation, 217, 220 Perioral dermatitis, 65, 144, 213, 217, 231, 232, Peristomal dermatoses, 30 Pharmaceuticals and Medical Devices Agency (PMDA), 293 Pharmacology ADRs, anti-inflammatory and immuno-suppressant effects, anti-proliferative action, 18 classification, 14, 15 contraindications, 20 formulations, geriatric and paediatric patients, 20 mechanism of action, potency, pregnancy and lactation, 20 selection and use, 19 structure-activity relationship, therapeutic indications, 18 vasoconstrictor action, 18 Pharmacovigilance, 292 active surveillance, 292 ADR, 292 adverse event, 292 CIOMS, 294 in Europe, 293 ICH guidelines, 294 in Japan, 293 passive surveillance, 292 in special population, 293 spontaneous reporting, 293 in US, 293 VigiBase, individual case safety report, WHO, Phimosis/labial adhesion, Phobia aetiology, 268 consequences, 268 management, Phospholipase A 2, 16
7 Photodermatitis, 199 Photosensitive eczema, 30 Photosensitivity, 146, 186, 200, 256, 273 Pigmentary disorders, 207 Pityriasis alba, 30 Plaque psoriasis, chronic, 112 Plasma cell balanitis, 162 Plasma cell vulvitis, 163 Polyamide, 106 Polymeric nanocarriers, 106 Post-inflammatory hypopigmentation, 114 Prednisolone, 13 Pregnancy cutaneous absorption and bioavailability in, 82 indications, 83 metabolism, randomized controlled trials, 65 recommendations, safety profile data, 83 effects of, fetal death, 84 fetal growth restriction, 84 orofacial cleft, 84 preterm delivery, 84 Preterm delivery, 84 Primary cicatricial alopecias (PCA), Profuse tinea, 231 Propionibacterium acnes, 256 Pseudoepitheliomatous micaceous, 163 Psoriasis, 31 children with, Koebner phenomenon, 322 randomized controlled trials, Purpura, 254 Pustules, 140 Pustulosis psoriasis, R Rebound phenomenon, 256 Red scrotum syndrome, 256 Red skin syndrome (RSS), 42, , 313 causes, 172 cortisol levels and progression, epidermis, 176 epidermal changes, 172, 173 epidermis with immunostaining, 172, clinical manifestation, management, 177 Rosacea, 193, 231, 232, Rosacea-like dermatitis, 255, 272 RSS. See Red skin syndrome (RSS) S Salicylic-mandelic acid, 279 Sarcoidosis, 36, 63 Scalp disorders alopecia areata, 103 intralesional steroids, topical corticosteroids in, 104 androgenetic alopecia, 105 categories, 102 cicatricial alopecias, EPDS, 106 formulations, polyamide, 106 polymeric nanocarriers, 106 scalp psoriasis, seborrhoeic dermatitis, 104 Scalp psoriasis, Scarring alopecia, 106 Schedule H, 74, 124, 182, 285, 304, 305 Seborrhoeic dermatitis (SD), 29, 65, 104 Selective glucocorticoid receptor agonists (SEGRAs), 20, 247 SIL. See Steroid-induced lipoatrophy (SIL) SIR. See Steroid-induced rosacea (SIR) Skin atrophy, 199, 233, 234 bleaching creams, 288 infection bacterial, 231, 232 mycoses, parasites, 231 viral, 232 Skinlite, 181 Small plaque psoriasis bioassay, 14 Soft corticosteroids, 13 Solar prurigo, 199 Southeast Asia, topical corticosteroid abuse, 210 acneiform eruptions, 213, adverse reactions, 221 axillary regions, 212 Cushing s syndrome, 221 factors, fungal infections, furunculosis and folliculitis, 217, 219, 220 guidelines, 221 inner arms, striae, 212 perilesional hypopigmentation, 217, 220 perioral dermatitis, 213, 217 potency, 221 psoriasis teenage, 211 psoriatic Indonesian patient, 212 psoriatic Singaporean patient, 211 skin atrophy, 212, 215 telangiectasia, 212, 214 Staphylococcus aureus, 29, 122, Stellate pseudoscars, Steroid acne, 198 Steroid-damaged skin, treatment saline injections, 273 SIL, 273, 274 SIR, 272 steroid-induced atrophy, steroid-induced striae, 273 Steroid dermatitis, 133 Steroid-induced atrophy, 113, Steroid-induced erythema, 113 Steroid-induced hypertrichosis, 114 Steroid-induced lipoatrophy (SIL), 273,
8 332 Steroid-induced rosacea (SIR), 272, 280 Steroid-induced striae, 273, 323 Steroid-modified tinea clinical presentations, 152 arciform lesions, double-edged tinea, 154 dumbbell-shaped large annular lesions, eczematous lesions, 154 larger-sized lesions, 152, 153 male genital dermatophytosis, multiple annular lesions, multiple small annular lesions, prominent striae and hypopigmentation, 157 tinea corporis, erythrodermic variant, 157 tinea cruris and corporis, 153 tinea faciei, 156, 157 tinea pseudoimbricata, morphological patterns, 152 veritable epidemic, 152 Steroid preatrophy, 28 Steroid rosacea, 183 Steroid withdrawal syndrome, 238 Striae, 146, 254, 281 distensae, Sulfonated shale oil cream, 264 Sulzberger, M.B, 4 Superficial dermatophytosis clinical presentations, 152 arciform lesions, double-edged tinea, 154 dumbbell-shaped large annular lesions, eczematous lesions, 154 larger-sized lesions, 152, 153 male genital dermatophytosis, multiple annular lesions, multiple small annular lesions, prominent striae and hypopigmentation, 157 tinea corporis, erythrodermic variant, 157 tinea cruris and corporis, 153 tinea faciei, 156, 157 tinea pseudoimbricata, problem, 152 Superficial infantile cutaneous hemangiomas, 64 Symptomatic oral LP, 60 T Tachyphylaxis, 197 Tar shampoos, 102 TCA. See Topical corticosteroid addiction (TCA) TCP. See Topical corticosteroid phobia (TCP) TCS. See Topical corticosteroid (TCS) Telangiectasia, 142, 193, 212, 214, 254, 280 Tinea corporis, 152, 157, 193, 218, 323 Tinea cruris, 153 Tinea faciei, 156, 157, 322, 323 Tinea incognita, 154, 230 Tinea incognito, 113, 143, Tinea pseudoimbricata, , 230, 231 Topical corticosteroid (TCS), 24 Index absorption, 26 administration frequency and treatment duration, chemical structure, 24 combination, 27 ethical issues beneficence vs. autonomy, non-malfeasance, 75 patient autonomy, 75 truth telling, 75 ethical use amount, frequency, and duration, 77 corticosteroid allergy, being aware of, 77 diagnosis, 76 effective communication, exit strategy, 77 molecule and delivery system, 76 patient, prevention and modifiable factors, focusing, 77 evolution adrenal extracts, 2 betamethasone, 6 clocortolone pivalate, 6 commercial side, 3 4 and development, 6 7 first topical use, 4 fluorinated agents, 4 5 local and systemic absorption, 6 planned serendipity, 2 3 Sulzberger and Witten, 4 ILS administration, 28 indications alopecia areata, atopic dermatitis, blistering disorders, burns, 35 children with psoriasis, chronic idiopathic urticaria and urticaria pigmentosa, 35 CLE, 33 contact dermatitis, 30 granulomatous diseases, 36 haemangiomas, 34 hand eczema and pityriasis alba, 30 intertrigo and perianal inflammation, 34 keloid and hypertrophic scars, 35 lichen planus, 32 lichen sclerosus, 35 LSC, 30 melasma, 35 mucocele, 36 nodulocystic acne, 36 peristomal dermatoses, 30 phimosis/labial adhesion, photosensitive eczema, 30 pretreatment, psoriasis, 31 sarcoidosis, 36 seborrhoeic dermatitis, 29 vitiligo, 33
9 333 misuse, global scenario, occlusive dressing therapy, 28 pregnancy and breastfeeding, safety in, pros and cons of bioavailability, 88 hydrocortisone, 87 preparation, potency ranking, 88 safety of, rational and ethical use abuse, 123 administrative measurement, 124 adverse effects, 123 combination with antibacterials, antifungals, indications, right choice of, 123 right education, right kind of patient, right potency, 119 right quantity, frequency, and duration, vehicle, side effects, 28 strength, 25 structure, systemic side effects, 244 cutaneous adverse reactions, factors, HPA axis suppression and iatrogenic Cushing s syndrome, 244, 245 hyperglycemia and metabolic disorders, 246 musculoskeletal system, ocular adverse effects, 246 pediatric and geriatric population, 247 percutaneous drug absorption, mechanism, 242 topical side effects, atrophy, bacterial infections, contact sensitization, delayed wound healing, 258 follicular changes, 255 fungal infections, 257 infestations, 257 pigmentary changes, 255 prevention, 258 rosacea and perioral dermatitis, viral infections, 257 vehicles and preparation, 27 Topical corticosteroid addiction (TCA), 42, dependence, 262 face, 263 genitalia and perianal area, 263 management, 264 pathogenesis, Topical corticosteroid phobia (TCP) aetiology, 268 consequences, 268 management, Topical steroid damaged/dependent face (TSDF), 183, 221, 302 aetiology and precipitating factors, clinical features, 149 definition, 138 dependence, 148 ethical use, facial skin, 138 acneiform eruptions, 141 allergic contact dermatitis, 145 atrophy and striae, 146 erythema, 139 hirsutism, 141, 142 hypo-and hyperpigmentation, 144 papules, 139 perioral dermatitis, 144 photosensitivity, 146 pustules, 140 rosacea-like features, 145 telangiectasia, 142 tinea incognito, 143 management, Topical steroid withdrawal (TSW), 169 Transcription factors, 16, 17, 92 Triamcinolone, 13, 103 Triamcinolone acetonide (TAC), abuse, 312 TSDF. See Topical steroid damaged/dependent face (TSDF) U Ulcers, 322, 324 Uppsala Monitoring Centre (UMC), Urticaria pigmentosa, 35 US Food and Drug Administration (USFDA), 293 UVB therapy, 31 V VigiBase, Viral skin infections, 232 Vitiligo, 33 associated with leucotrichia, 112 meta-analysis, 52 randomized controlled trials, systematic review, 52 Vulvar lichen sclerosus atrophicus (VLS), W Witten, V.H., 4 Y Yellow Card Scheme, 293 Z Zoon s balanitis, 162, 166
Prescribing Information
Prescribing Information Pr DERMOVATE Cream (clobetasol propionate cream, USP) Pr DERMOVATE Ointment (clobetasol propionate ointment, USP) Topical corticosteroid TaroPharma Preparation Date: A Division
More informationTable of Contents: Part 1 Medical Dermatology. Chapter 1 Acneiform Disorders. Acne. Acne Vulgaris. Pomade Acne. Steroid Acne
Table of Contents: Part 1 Medical Dermatology Chapter 1 Acneiform Disorders Acne Acne Vulgaris Pomade Acne Steroid Acne Infantile Acne Pediatric Perspectives Neonatal Acne (Acne Neonatorum) Pediatric Perspectives
More informationPrescribing Information. Taro-Clobetasol. Taro-Clobetasol
Prescribing Information Pr Taro-Clobetasol Clobetasol Propionate Cream USP, 0.05% w/w Pr Taro-Clobetasol Clobetasol Propionate Ointment USP, 0.05% w/w Therapeutic Classification Topical corticosteroid
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Excipient with known effect Cetyl alcohol For the full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Haelan Ointment Fludroxycortide 0.0125% w/w Ointment 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Fludroxycortide 0.0125% w/w. Excipient
More informationTOPCORT Cream/Ointment (Mometasone furoate 0.1%)
Published on: 10 Jul 2014 TOPCORT Cream/Ointment (Mometasone furoate 0.1%) Composition TOPCORT Cream Mometasone Furoate, IP... 0.1% w/w In a cream base... q.s. TOPCORT Ointment Mometasone Furoate, IP...
More informationPRODUCT INFORMATION ELEUPHRAT CREAM, OINTMENT AND LOTION. Betamethasone dipropionate equivalent to betamethasone 0.5 mg/g (0.
PRODUCT INFORMATION ELEUPHRAT CREAM, OINTMENT AND LOTION NAME OF THE MEDICINE Betamethasone dipropionate equivalent to betamethasone 0.5 mg/g (0.05% w/w) Chemical Structure: Betamethasone dipropionate
More information50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate).
DUPISOR Composition Gel 50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate). Action Calcipotriol is a non-steroidal antipsoriatic agent, derived from vitamin D. Calcipotriol
More informationDATA SHEET. Betamethasone dipropionate equivalent to betamethasone 0.5mg/g (0.05% w/w).
DATA SHEET 1. DIPROSONE DIPROSONE (0.05% w/w) cream DIPROSONE (0.05% w/w) ointment 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Betamethasone dipropionate equivalent to betamethasone 0.5mg/g (0.05% w/w).
More informationDIPROSONE OV Cream and Ointment do not contain preservatives, parabens or lanolin.
PRODUCT INFORMATION DIPROSONE OV (OPTIMISED VEHICLE) CREAM AND OINTMENT NAME OF THE MEDICINE DIPROSONE OV Cream and Ointment (Betamethasone dipropionate) Chemistry Abstracts Service (CAS) registry number:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ovixan 1 mg/g cream 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One gram cream contains 1 mg mometasone furoate Excipients with known
More informationBETNOVATE Betamethasone 17-valerate
BETNOVATE Betamethasone 17-valerate Betamethasone valerate is referred to as Betnovate throughout this information. PRESENTATION BETNOVATE Cream (non-greasy base) 0.1% betamethasone as 17-valerate in a
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Flutarzole 0,05% w/w cream, Fluticasone propionate
PACKAGE LEAFLET: INFORMATION FOR THE USER Flutarzole 0,05% w/w cream, Fluticasone propionate 1. IDENTIFICATION OF THE MEDICINAL PRODUCT 1.1. Trade name Flutarzole 1.2. Composition Active substance: Fluticasone
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Haelan Tape Fludroxycortide 4 micrograms per square centimetre Tape 2. QUALITATIVE AND QUANTITATIVE COMPOSITION The tape is impregnated
More informationIndex. derm.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abatacept for DLE, 493 for SLE, 497 Ablative therapies, localized, for cutaneous T-cell lymphoma, 502 506. See also Cutaneous T-cell lymphoma,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Monovo 1 mg/g cutaneous emulsion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of cutaneous emulsion contains 1 mg mometasone
More informationNOVASONE CREAM, OINTMENT AND LOTION PRODUCT INFORMATION
NAME OF THE MEDICINE Mometasone furoate 0.1% (1 mg/g) Chemical structure: NOVASONE CREAM, OINTMENT AND LOTION PRODUCT INFORMATION Mometasone furoate is 9,21-dichloro-11ß,17-dihydroxy-16 -methylpregna-1,4-diene-
More informationBETNOVATE SKIN CREAM. Betamethasone Valerate Cream IP QUALITATIVE AND QUANTITATIVE COMPOSITION
For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory BETNOVATE SKIN CREAM Betamethasone Valerate Cream IP QUALITATIVE AND QUANTITATIVE COMPOSITION BETNOVATE Skin Cream contains:
More informationTopical Corticosteroid Abuse in Dermatology
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 7 Ver. IX (July. 2016), PP 110-114 www.iosrjournals.org Topical Corticosteroid Abuse in Dermatology
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Psoriasis (excluding widespread plaque psoriasis) Psoriasis is a common chronic skin disorder. Estimates of the prevalence (proportion
More informationFluocinolone Acetonide 0.01% Topical Oil (Scalp Oil)
Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil) For Topical Use Only- Not for Oral, Ophthalmic, or Intravaginal Use DESCRIPTION Fluocinolone Acetonide 0.01% Topical Oil contains fluocinolone acetonide
More informationPRESCRIBING INFORMATION. ratio-topisone. Betamethasone dipropionate USP. 0.5 mg Cream, Ointment and Lotion. Topical corticosteroid
PRESCRIBING INFORMATION ratio-topisone Betamethasone dipropionate USP 0.5 mg Cream, Ointment and Lotion Topical corticosteroid Teva Canada Limited Date of Revision 30 Novopharm Court January 21, 2013 Toronto,
More informationPRODUCT MONOGRAPH DIPROSONE. Betamethasone Dipropionate Cream, Merck Standard, 0.05% W/W betamethasone (as dipropionate)
PRODUCT MONOGRAPH DIPROSONE Betamethasone Dipropionate Cream, Merck Standard, Betamethasone Dipropionate Ointment, Merck Standard, Betamethasone Dipropionate Lotion, USP, Topical Corticosteroid Merck Canada
More informationUltravate (halobetasol propionate) Cream, 0.05% (halobetasol propionate) Ointment, 0.05% For Dermatological Use Only. Not for Ophthalmic Use.
Ultravate (halobetasol propionate) Cream, 0.05% (halobetasol propionate) Ointment, 0.05% For Dermatological Use Only. Not for Ophthalmic Use. Rx only DESCRIPTION Ultravate contains halobetasol propionate,
More informationHYDROCORTISONE OINTMENT USP,
HYDROCORTISONE- hydrocortisone ointment E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. ---------- HYDROCORTISONE OINTMENT USP, 1% Rx only For External Us e Only Not For Ophthalmic Us e DESCRIPTION:
More informationContents. QAaptm-2. CAaptei-3. CAaptm-4. Cftapte%-5. Qfiaptvt-6. QhapteK-7. Qkaptefc-8 Clinical Immunology and Allergy 71
Contents Ckaptm-1 Aaatomy, Physiology, Embryology, Bacteriology and Pathology ~ 1 Anatomy 1 Physiology 10 Embryology 14 Pathology 19 Bacteriology 22 Laboratory and other aids in dermatological pratice
More informationResearch Article. Pattern of utilization of corticosteroids in department of dermatology at a tertiary care teaching hospital
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2014, 6(8):86-91 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 Pattern of utilization of corticosteroids in department
More informationChemically, clobetasol propionate is 21-chloro-9-fluoro,11β,17-dihydroxy-16βmethylpregna-1,4-diene-3,20-dione
Clobetasol Propionate Cream USP, 0.05% FOR TOPICAL DERMATOLOGIC USE ONLY NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE. DESCRIPTION Clobetasol propionate cream USP, 0.05% contain the active compound clobetasol
More informationDESCRIPTIONS FOR MED 3 ROTATIONS Dermatology A3S
Regardless of your future field of practice, you will be exposed to a considerable amount of dermatology and this rotation provides you the chance to see a range of skin diseases. You will have the opportunity
More informationGROUP 15 TOPICAL PREPARATIONS
- 105 - GROUP 15 15.1 DERMATOLOGICAL PREPARATIONS 15.1.1 TOPICAL ANTIFUNGALS CLOTRIMAZOLE Indication: Treatment of susceptible fungal infections, dermatophytoses, superficial mycoses, and cutaneous candidiasis
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory TENOVATE TM. Clobetasol Cream IP/ Clobetasol Ointment IP
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory TENOVATE TM Clobetasol Cream IP/ Clobetasol Ointment IP QUALITATIVE AND QUANTITATIVE COMPOSITION TENOVATE Cream contains:
More informationIndex. Angiosarcoma diagnosis, 47 lymphedema-related vs. non-lymphedemarelated, 48
A Acneiform rash biopsy, 134 cetuximab, EGFR, 132 133 diagnosis, 131 patient history, 131 134 treatment, 134 135 Acne vulgaris, 109 AGA. See Androgenetic alopecia Alopecia areata, 148 American Joint Committee
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory BETNOVATE C SKIN CREAM. Betamethasone and Clioquinol Cream BP
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory BETNOVATE C SKIN CREAM Betamethasone and Clioquinol Cream BP QUALITATIVE AND QUANTITATIVE COMPOSITION BETNOVATE C SKIN
More informationPRODUCT MONOGRAPH. Betamethasone dipropionate USP. 0.5 mg Cream, Ointment and Lotion. Topical corticosteroid
PRODUCT MONOGRAPH Pr TEVA-TOPISONE Betamethasone dipropionate USP 0.5 mg Cream, Ointment and Lotion Topical corticosteroid Teva Canada Limited Date of Revision 30 Novopharm Court October 25, 2018 Toronto,
More informationFor topical use only. Not for oral, ophthalmic, or intravaginal use.
DESOXIMETASONE Ointment USP, 0.25% For topical use only. Not for oral, ophthalmic, or intravaginal use. Rx only DESCRIPTION Desoximetasone ointment USP, 0.25% contains the active synthetic corticosteroid
More informationZOFLUT Cream (Fluticasone propionate)
Published on: 23 Sep 2014 ZOFLUT Cream (Fluticasone propionate) Composition ZOFLUT Cream contains: Fluticasone Propionate,BP 0.05% w/w In a cream base.q.s. Dosage Form Topical cream Pharmacology Pharmacodynamics
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory BETNOVATE - S
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory BETNOVATE - S Betamethasone Valerate and Salicylic Acid Skin Ointment QUALITATIVE AND QUANTITATIVE COMPOSITION BETNOVATE
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Each gram of ointment contains 1 mg of mometasone furoate and 50 mg of salicylic acid
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Elosalic 1 mg/g + 50 mg/g ointment. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each gram of ointment contains 1 mg of mometasone furoate
More informationThere s comfort in the familiar
When treating corticosteroid-responsive dermatoses... [ Be sure to write Psorcon (diflorasone) Cream ] Diflorasone Diacetate Cream, 0.05%, 60 g $ 0 Benefits to the healthcare professional: There s comfort
More informationCLINICAL PHARMACOLOGY
ELOCON brand of mometasone furoate ointment Ointment 0.1% For Dermatologic Use Only Not for Ophthalmic Use DESCRIPTION ELOCON (mometasone furoate ointment) Ointment, 0.1%, contains mometasone furoate,
More informationLUMACIP PLUS Cream (Fluocinolone acetonide 0.01% + Hydroquinone 4% + Tretinoin 0.05%)
Published on: 10 Jul 2014 LUMACIP PLUS Cream (Fluocinolone acetonide 0.01% + Hydroquinone 4% + Tretinoin 0.05%) Composition LUMACIP PLUS Cream Each gram contains: Fluocinolone acetonide IP.. 0.01% w/w
More informationEach gram of the ointment contains 0.25 mg Fluocinolone Acetonide in a base containing White Petrolatum.
FLUOCINOLONE ACETONIDE- fluocinolone acetonide ointment E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. ---------- FLUOCINOLONE ACETONIDE OINTMENT, USP, 0.025% For Topical Us e Only. Not for
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory FLUTIVATE SKIN CREAM. Fluticasone Cream IP
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory FLUTIVATE SKIN CREAM Fluticasone Cream IP QUALITATIVE AND QUANTITATIVE COMPOSITION Fluticasone Propionate IP 0.05% w/w
More informationTopical corticosteroid abuse on face: a clinical study of 100 patients
International Journal of Research in Dermatology Bains P. Int J Res Dermatol. 2016 Sep;2(3):40-45 http://www.ijord.com Research Article DOI: http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20163105
More informationStudy of prescribing pattern of topical corticosteroids in dermatology out patients department in a Tertiary Care Hospital in Puducherry
Manju et al / International Journal of Pharmacological Research 2018; 8(1): 01-05. 1 International Journal of Pharmacological Research ISSN: 2277-3312 (Online) Journal DOI: https://doi.org/10.7439/ijpr
More informationPRESCRIBING INFORMATION. Cream 0.025% Topical Corticosteroid
PRESCRIBING INFORMATION Pr PROPADERM (beclomethasone dipropionate) Cream 0.025% Topical Corticosteroid Valeant Canada LP 2150 St-Elzear Blvd. West, Laval, Quebec, Canada H7L 4A8 Date of preparation: October
More informationSite and distribution: symmetrical, asymmetrical. Surface characteristics: smooth, scaly, warty
B I O T E R R O R I S M PRINCIPLES AND PRACTICE OF DERMATOLOGY Dr Matthew Ng Joo Ming INTRODUCTION Medical schools and textbooks teach us dermatology by subjects such as eczema and psoriasis. This is useful
More informationCONDITIONS OF THE SKIN
CONDITIONS OF THE SKIN UCSF/SFGH Family & Community Medicine Residency Program Educational Objectives I. Knowledge The resident will be able to discuss the definition, diagnosis, and initial management
More informationTopical steroids - fairness fervour to fallout
International Journal of Research in Dermatology Hogade AS et al. Int J Res Dermatol. 2017 Jun;3(2):234-238 http://www.ijord.com Original Research Article DOI: http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20172203
More informationVulval dermatoses. Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough
Vulval dermatoses Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough Pigmentation Vulvodynia Ulcers Genetic Pruritus VULVAL
More informationWR SKIN. DERMATOLOGY
WR SKIN. DERMATOLOGY 1 Societies 11 History 13 Dictionaries. Encyclopaedias. Bibliographies Use for general works only. Classify with specific aspect 15 Classification. Nomenclature 16 Tables. Statistics
More informationCordran Cream and Cordran Ointment Flurandrenolide, USP
Cordran Cream and Cordran Ointment Flurandrenolide, USP DESCRIPTION Cordran (flurandrenolide, USP) is a potent corticosteroid intended for topical use. Flurandrenolide occurs as white to off-white, fluffy,
More informationNEW ZEALAND DATA SHEET
EUMOVATE Cream NEW ZEALAND DATA SHEET Name of each active ingredient Clobetasone 17-Butyrate BP 0.05% w/w Presentations Eumovate Cream is white in appearance and contains 0.05% w/w clobetasone butyrate.
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adhesive tape impression 1 Diff Quik in EPD diagnosis, 583 Allergy(ies). See also Food allergy; specific types, e.g., Culicoides hypersensitivity
More informationATTACHMENT 1 SUMMARY OF PRODUCT CHARACTERISTICS
ATTACHMENT 1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Locoid Lipocream 0.1% cream 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Locoid Lipocream contains 1 mg/g hydrocortisone
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cutivate 0.005% w/w Ointment. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Fluticasone Propionate (micronised) HSE 0.005% w/w. Excipients
More informationRevised: 03/2018. *Sections or subsections omitted from the full prescribing information are not listed.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DIPROLENE Ointment safely and effectively. See full prescribing information for DIPROLENE Ointment.
More informationNEW ZEALAND DATA SHEET 1 LOCOID 2 QUALITATIVE AND QUANTITATIVE COMPOSTION 3 PHARMACEUTICAL FORM 4 CLINICAL PARTICULARS
NEW ZEALAND DATA SHEET 1 LOCOID Lipocream Ointment Topical Emulsion (Locoid Crelo ) Scalp Lotion hydrocortisone butyrate 2 QUALITATIVE AND QUANTITATIVE COMPOSTION Each formulation contains active ingredient
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME KENACOMB ear drops NEW ZEALAND DATA SHEET 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g contains the following active ingredients: 0.025% gramicidin, 0.25% neomycin, 100,000 units nystatin,
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Etrivex 500 micrograms/g shampoo Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of shampoo contains 500 micrograms of clobetasol
More informationPRODUCT MONOGRAPH. Taro-Mometasone Cream (Mometasone Furoate Cream, USP) 0.1% (w/w)
PRODUCT MONOGRAPH Pr Taro-Mometasone Cream (Mometasone Furoate Cream, USP) 0.1% (w/w) Pr Taro-Mometasone Ointment (Mometasone Furoate Ointment, USP) 0.1% (w/w) Pr Taro-Mometasone Lotion (Mometasone Furoate
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: 03/2018
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DIPROLENE Lotion safely and effectively. See full prescribing information for DIPROLENE Lotion. DIPROLENE
More informationElocon (mometasone furoate) Cream, Ointment, and Lotion Formulations : Core Safety Profile
Elocon (mometasone furoate) Cream, Ointment, and Lotion Formulations : Core Safety Profile 4.3 Contraindications Elocon is contraindicated in facial rosacea, acne vulgaris, skin atrophy, perioral dermatitis,
More informationNEW ZEALAND DATA SHEET. Excipients with known effect include cetostearyl alcohol and chlorocresol.
NEW ZEALAND DATA SHEET DERMOL 1. Product Name Dermol, 0.05% w/w, cream. Dermol, 0.05% w/w, ointment. 2. Qualitative and Quantitative Composition Each 1 g of cream or ointment contains 0.5 mg of clobetasol
More informationDERMATOP Ointment (prednicarbate ointment) 0.1% FOR DERMATOLOGIC USE ONLY. NOT FOR USE IN EYES.
DERMATP intment (prednicarbate ointment) 0.1% FR DERMATLGIC USE NLY. NT FR USE IN EYES. DESCRIPTIN DERMATP intment (prednicarbate ointment) 0.1% contains the non-halogenated prednisolone derivative prednicarbate.
More informationFLUOCINOLONE ACETONIDE-
FLUOCINOLONE ACETONIDE- fluocinolone acetonide cream E. & Co. a division of Pharmaceuticals Inc. ---------- FLUOCINOLONE ACETONIDE CREAM, USP 0.01%, 0.025% For Topical Us e Only. Not for Ophthalmic Us
More informationMETHYLPREDNISOLONE ACEPONATE (MPA)
RE AFETY PRFILE ETHYLPREDNILNE AEPNATE (PA) 4.2 Posology and method of administration PA is to be applied thinly once daily to the affected areas and rubbed in lightly. PA cream/ointment/fatty ointment:
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET DERMOL 1. Product Name Dermol, 0.05% w/w, scalp lotion. 2. Qualitative and Quantitative Composition Each 1 g of scalp lotion contains 0.5 mg of clobetasol propionate. For the full
More informationCore Safety Profile. AT/H/PSUR/0013/002 Date of FAR:
ore afety Profile Active substance: Methylprednisolon aceponate Pharmaceutical form(s)/strength: ream / 0.1 % Fatty ointment / 0.1 % utaneous emulsion / 0.1 % intment / 0.1 % utaneous solution / 0.1 %
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Hydrocortisone Ointment 1% 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Ointment containing 1% micronised hydrocortisone Excipient(s)
More informationPhototherapy and Photochemotherapy Treatment (Ultraviolet A [PUVA] and B [UBV])
Origination: 09/27/07 Revised: 08/2/17 Annual Review: 11/2/17 Purpose: To provide Phototherapy and Photochemotherapy Treatment (PUVA and UBV) guidelines for the Medical Department staff to reference when
More informationKEY MESSAGES. Psoriasis patients are more prone to cardiovascular diseases, stroke, lymphoma and non-melanoma skin cancers, and increased mortality.
KEY MESSAGES Psoriasis is a genetically determined, systemic immune-mediated chronic inflammatory disease that affects primarily the skin and joints. Psoriasis Vulgaris is characterised by well-demarcated
More informationDIPROLENE AF (augmented betamethasone dipropionate) Cream, 0.05% for topical use Initial U.S. Approval: 1983
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DIPROLENE AF Cream safely and effectively. See full prescribing information for DIPROLENE AF Cream.
More informationProvide relief with Topicort 0.05% 1,2. For your patients with corticosteroid-responsive dermatoses... IMPORTANT SAFETY INFORMATION
For your patients with corticosteroid-responsive dermatoses... SPREAD THE Provide relief with Topicort 0.05% 1,2 Group C molecule 3 Low allergenic potential 4-6 Available in cream and ointment 3,7 Topicort
More informationELOCON (mometasone furoate) Ointment, 0.1% for topical use Initial U.S. Approval: 1987
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ELOCON Ointment safely and effectively. See full prescribing information for ELOCON Ointment. ELOCON
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS. NAME OF THE MEDICINAL PRODUCT Daivobet 50 micrograms/g + 0.5 mg/g gel 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of gel contains 50 micrograms of calcipotriol
More informationPRODUCT MONOGRAPH ELOCOM. Mometasone Furoate Cream, BP, 0.1% Mometasone Furoate Ointment, Merck Standard, 0.1% Mometasone Furoate Lotion, 0.
PRODUCT MONOGRAPH ELOCOM Mometasone Furoate Cream, BP, 0.1% Mometasone Furoate Ointment, Merck Standard, 0.1% Mometasone Furoate Lotion, 0.1% Topical Corticosteroid Therapy Merck Canada Inc. 16750 route
More informationRashes Not To Be Missed In Children
May 2016 Rashes Not To Be Missed In Children Dr Chan Yuin Chew Dermatologist Dermatology Associates Gleneagles Medical Centre Scope of presentation Focus on rashes May lead to significant morbidity if
More informationUndergraduate Dermatology Curriculum July 2016
Undergraduate Dermatology Curriculum July 2016 British Association of Dermatologists Introduction This document is the 2016 revised dermatology undergraduate curriculum (UK) from the British Association
More informationCLOBEX SHAMPOO PRODUCT INFORMATION
CLOBEX SHAMPOO PRODUCT INFORMATION NAME OF THE MEDICINE CLOBEX Shampoo: clobetasol propionate 500 micrograms/ml Australian Approved Name (AAN): clobetasol propionate Common Name: clobetasol propionate
More informationThe side effects of prolonged used of systemic Corticosteroids
The side effects of prolonged used of systemic Corticosteroids -Lowering the resistance to many infections. -Metabolic disturbance, particularly in regard to electrolytes and carbohydrates leading to fluid
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Calcipotriol/Betamethason Sandoz 50 microgram/g + 0,5 mg/g, zalf
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Calcipotriol/Betamethason Sandoz 50 microgram/g + 0,5 mg/g, zalf 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of ointment contains
More informationThursday, 21 October :53 - Last Updated Thursday, 11 November :27
1 / 15 2 / 15 3 / 15 4 / 15 Pityriasis Alba Background Pityriasis alba is a nonspecific dermatitis of unknown etiology that causes erythematous scaly patches. These resolve and leave areas of hypopigmentation
More informationYour health is our priority
Your health is our priority Pharmaderm laboratories, founded in 1986, are among the first Tunisian pharmaceutical laboratories. Wealth of an experience of 25 years in the pharmaceutical field, Pharmaderm
More informationSubspecialty Rotation: Dermatology
Subspecialty Rotation: Dermatology Faculty: Wesley Galen, M.D. GOAL: Prevention, Counseling and Screening (Dermatology). Understand the pediatrician's role in preventing illness and dysfunction related
More informationTopical steroid abuse on face: a prospective study from a tertiary care centre of north India
International Journal of Research in Dermatology Nyati A et al. Int J Res Dermatol. 2017 Sep;3(3):433-438 http://www.ijord.com Original Research Article DOI: http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20173926
More informationRevised: 05/2018. *Sections or subsections omitted from the full prescribing information are not listed.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ELOCON Lotion safely and effectively. See full prescribing information for ELOCON Lotion. ELOCON
More informationDermatology GP Referral Guidelines
Austin Health Dermatology Department holds 5 Clinic sessions to discuss and plan the treatment of with Dermatology conditions. Department of Health clinical urgency categories for specialist clinics Urgent:
More informationCLINICAL PHARMACOLOGY Like other topical corticosteroids, clobetasol propionate has anti-inflammatory, antipruritic, and
CLOBETASOL PROPIONATE- clobetasol propionate ointment Glenmark Pharmaceuticals Inc., USA ---------- Clobetas ol Propionate Ointment USP, 0.05% Rx Only FOR TOPICAL DERMATOLOGIC USE ONLY- NOT FOR OPHTHALMIC,
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory TENOVATE M. Clobetasol Propionate and Miconazole Nitrate Skin Cream
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory TENOVATE M Clobetasol Propionate and Miconazole Nitrate Skin Cream QUALITATIVE AND QUANTITATIVE COMPOSITION TENOVATE M
More informationCutanous Manifestation of Lupus Erythematosus. Presented By: Dr. Naif S. Al Shahrani Salman Bin Abdaziz university
Cutanous Manifestation of Lupus Erythematosus Presented By: Dr. Naif S. Al Shahrani Salman Bin Abdaziz university A 50-year old lady, who is otherwise healthy, presented to the dermatology clinic with
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory EUMOSONE. Clobetasone Cream IP
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory EUMOSONE Clobetasone Cream IP QUALITATIVE AND QUANTITATIVE COMPOSITION EUMOSONE contains : Clobetasone Butyrate IP 0.05
More informationCOPYRIGHTED MATERIAL. Introduction CHAPTER 1. Introduction
CHAPTER 1 Introduction OVERVIEW The clinical features of skin lesions are related to the underlying pathological processes. Broadly skin conditions fall into three clinical groups: (a) those with a well-defined
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
NEW ZEALAND DATA SHEET 1. PIMAFUCORT Cream Ointment Hydrocortisone, natamycin and neomycin sulphate 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Cream per gram: 10mg hydrocortisone, 10mg natamycin and 3.5mg
More informationDermatology Pearls. Leah Layman, ARNP Jefferson Healthcare Dermatology June 21, 2018
Dermatology Pearls Leah Layman, ARNP Jefferson Healthcare Dermatology June 21, 2018 What s on the agenda? Common skin conditions and where to start with treatment Gentle skin care regimen PCP and Biologics
More informationCORTISPORIN Cream (neomycin and polymyxin B sulfates and hydrocortisone acetate cream, USP)
CORTISPORIN Cream (neomycin and polymyxin B sulfates and hydrocortisone acetate cream, USP) DESCRIPTION CORTISPORIN Cream (neomycin and polymyxin B sulfates and hydrocortisone acetate cream, USP) is a
More informationAtopic Eczema with detail on how to apply wet wraps
Atopic Eczema with detail on how to apply wet wraps Dr Carol Hlela Consultant Dermatologist Head of Unit, Department of Dermatology, Paediatrics Red Cross Children s Hospital, UCT Red Cross War Memorial
More informationMy ear won t stop hurting!
This month: 1. My ear won t stop hurting! 5. Cortisone Cream Didn t Help! 2. What are these red bumps? 6. Can my girlfriend get it? 3. Why won t this rash leave? 7. My wife noticed it! 4. What s the cause
More informationHydroVal (Hydrocortisone Valerate)
PRODUCT MONOGRAPH HydroVal (Hydrocortisone Valerate) Cream & Ointment 0.2 % Topical Corticosteroid TaroPharma Preparation Date: A Division of Taro Pharmaceuticals Inc. Sept 02, 2003 130 East Drive Brampton,
More information